Compare RBA & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RBA | JAZZ |
|---|---|---|
| Founded | 1958 | 2003 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.0B | 16.1B |
| IPO Year | 1997 | 2007 |
| Metric | RBA | JAZZ |
|---|---|---|
| Price | $85.99 | $241.73 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 14 |
| Target Price | $122.20 | ★ $217.57 |
| AVG Volume (30 Days) | ★ 1.7M | 869.5K |
| Earning Date | 05-04-2026 | 05-05-2026 |
| Dividend Yield | ★ 1.18% | N/A |
| EPS Growth | ★ 1.49 | N/A |
| EPS | 1.37 | ★ 7.17 |
| Revenue | ★ $4,590,700,000.00 | $1,618,693,000.00 |
| Revenue This Year | $4.43 | $6.22 |
| Revenue Next Year | $6.65 | $7.68 |
| P/E Ratio | $62.85 | ★ $33.59 |
| Revenue Growth | ★ 7.15 | N/A |
| 52 Week Low | $79.75 | $124.50 |
| 52 Week High | $119.58 | $266.38 |
| Indicator | RBA | JAZZ |
|---|---|---|
| Relative Strength Index (RSI) | 38.62 | 49.93 |
| Support Level | $82.03 | $237.05 |
| Resistance Level | $88.69 | $250.49 |
| Average True Range (ATR) | 1.95 | 6.76 |
| MACD | 0.74 | -0.50 |
| Stochastic Oscillator | 52.09 | 37.55 |
RB Global has evolved into a leading global marketplace that connects buyers and sellers of commercial assets and vehicles. It is the result of the 2023 combination of Ritchie Bros. and IAA. Ritchie Bros.' roots were as an auctioneer facilitating transactions of commercial, construction, and transportation equipment (excavators, bulldozers, forklifts, and commercial trucks and trailers). However, it has evolved into an omnichannel marketplace. IAA has similar roots, though primarily focused on the salvage auction segment for consumer automobiles. The group provides ancillary services including title processing, transportation/towing, financing, data and appraisal, and so on. Its activities are international, though skewing approximately two-thirds to North America.
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.